According to CoinMeta, Xuantai Medicine announced that its application for a generic version of posaconazole enteric-coated tablets has been officially approved by the Colombian National Agency for Food and Drugs (INVIMA), with the marketing authorization number 2026072821. The product is in tablet form and comes in a 100mg dosage. It is primarily used for the treatment of invasive aspergillosis or candidiasis infections. This is the first generic drug approved by the US FDA and China NMPA, and it has already been approved in multiple countries and regions. This approval signifies that the company is now qualified to sell this product in the Colombian market, representing an important milestone for the company in the Latin American market. It will have a positive impact on the company's long-term operations, although there is uncertainty regarding its short-term financial effects.